A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury
A Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Cognition and Neuropsychiatric Symptoms in Patients With a History of Acquired Brain Injuries
Sponsor: Lieber Institute for Brain Development
Listed as NCT03273062, this PHASE2 trial focuses on Brain Injuries and Brain Injuries, Traumatic and remains ongoing. Sponsored by Lieber Institute for Brain Development, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lieber Institute for Brain Development
- Sheppard Pratt Health System
For direct contact, visit the study record on ClinicalTrials.gov .